Interferon α (IFNα) has been demonstrated to possess a significant biological activity for cutaneous malignant melanoma (CMM). Although multiple adjuvant trials utilizing IFNa have been tested, no consensus on the optimal dosing schedule has been reached. From February 1993 to October 1997 we enrolled 86 CMM patients using low doses of IFNα-2b (3 MU/d TIW SC for 3 years) in a phase II study. Our present data show a median disease-free survival (DFS) of 30 months (range 2-62), comparable to those obtained in high-dose IFNα trials. These findings suggest that positive results may be also obtained using low doses of IFNa in adjuvant treatment of CMM patients. In contrast to the high dose, the low dose regimen was well tolerated with an acceptable quality of life of patients.
3-year treatment with recombinant interferon-α as adjuvant therapy of cutaneous malignant melanoma
Palmieri G.;
1999
Abstract
Interferon α (IFNα) has been demonstrated to possess a significant biological activity for cutaneous malignant melanoma (CMM). Although multiple adjuvant trials utilizing IFNa have been tested, no consensus on the optimal dosing schedule has been reached. From February 1993 to October 1997 we enrolled 86 CMM patients using low doses of IFNα-2b (3 MU/d TIW SC for 3 years) in a phase II study. Our present data show a median disease-free survival (DFS) of 30 months (range 2-62), comparable to those obtained in high-dose IFNα trials. These findings suggest that positive results may be also obtained using low doses of IFNa in adjuvant treatment of CMM patients. In contrast to the high dose, the low dose regimen was well tolerated with an acceptable quality of life of patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
